Orion Pharma Animal Health News and Activities

Orion Pharma Animal Health is owned by Orion Pharma.

Orion Pharma is one of the...

• Stoxx 600;
• TOB Iconic 10,000.

Orion Pharma is a company listed under the stock ticker ORINY (FI).

They are in:

• Pharmaceuticals67%
• Biotechnology33%

View the org chart displaying its 8 main executives

Most searched biographies at Orion Pharma Animal Health

• Niclas Lindstedt, Senior Vice President
• Simon Boulton, Global Marketing Director
• Jon Engeseth, Head, Nordics and Central Eastern Europe

Popular executive movements at Orion Pharma

• Christina Villumsen has joined the company as Vice President, Corporate Communications, Brand and Public Affairs  (posted on April 27 2026).
• Berkeley Vincent will join the company as Executive Vice President, Innovative Medicines on Apr. 8, 2026  (posted on April 1 2026).
• Outi Vaarala who was Senior Vice President, Innovative Medicines and Research & Development, becomes Senior Vice President, Research & Development  (posted on April 1 2026).

Click here to view some more movements at Orion Pharma

Create your alert
to follow the executive moves at Orion Pharma Animal Health.

Orion Pharma has 2,405 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ona Therapeutics has just announced a $87 Million fundraising (posted on June 5 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Carl Gordon - Director at Odyssey Therapeutics

Learn more about the Biotechnology industry

Press releases by Orion Pharma Animal Health

• Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
• Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting
• 105,950 Orion Corporation A shares converted into B shares
• Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs
• A stable society does not appear out of the blue – Orion and CMI open discussions about lasting peace in an evolving world
• Early diagnosis gives better outcomes – Taking control of asthma from the start
• Orion Group Interim report January–March 2026
• Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours
• Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA
• The patient journey starts with listening: Why the human side of healthcare matters
• View more press releases Close

Social media about Orion Pharma Animal Health

• Orion Pharma Animal Health on Wikipedia, Google News & Yahoo Finance
• Orion Pharma Animal Health on LinkedIn, X (Twitter) & YouTube